During the coming five years, Truly Labs will together with researchers at Lund University play a significant role in the European project TRISTAN (Translational Imaging in Drug Safety Assessment), funded in part by the Innovative Medicines Initiative (IMI). The objective is to develop imaging tools for safety assessment of new drugs and drugs in development, specifically for lung and liver toxicity and bio-distribution of biologics.
TRISTAN brings together experts from academia, research organizations, Small-to-Medium sized Enterprises (SMEs), industries, and pharmaceutical companies, thus providing a unique set of competence to deliver new tools for early detection of drugs with severe side effects.
With extensive knowledge and experience in translational science, lung biology and development of in vivo models, Truly Labs will be an important contributor to the part of the project focused on lung imaging biomarkers. The preclinical development and qualification of new lung imaging biomarkers will be done in close collaboration with researchers at Lund University and Lund University Bioimaging Center, who have solid expertise in lung imaging as well as state of the art imaging equipment.
Truly Labs is one of three SMEs that eventually will provide commercial services based on the qualified imaging biomarkers in each respective area. This will ensure sustainability of the developed biomarkers and offer pharmaceutical and biotech companies access to valuable safety assessment imaging tools.
For further information regarding TRISTAN, please see the TRISTAN press release
PDF: Truly Labs a Partner in a €24 Million European Consortium TRISTAN
For further information regarding Truly Labs' participation in TRISTAN, please contact:
Karin von Wachenfeldt, CEO, Truly Labs,
email: Karin@trulylabs.com, phone: +46 723 111 589